Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Schizophrenia affects 1% of the population, with unmet needs for cognitive and negative symptom treatments.
• Neuroimaging research is advancing understanding of schizophrenia pathophysiology and drug targets.
• Validated biomarkers are crucial but currently lacking for novel therapeutic development.

Purpose of the Study:

• To review the role of neuroimaging in clinical drug development for psychotic disorders.
• To highlight neuroimaging's contribution to target discovery, engagement, and dose selection.
• To discuss the potential and limitations of neuroimaging biomarkers in drug development.

Main Methods:

• Review of current neuroimaging technologies and their application in drug development.
• Examination of case studies, such as NMDA receptor hypofunction targets.
• Analysis of pharmacological neuroimaging in healthy volunteers and patient populations.

Main Results:

• Neuroimaging is critical for target discovery, engagement, and dose selection in drug development programs.
• Pharmacological neuroimaging can offer response biomarkers for early decision-making in proof-of-concept studies.
• Biomarker evaluation in patient populations is limited, with ongoing challenges in validation.

Conclusions:

• Neuroimaging plays a vital role in advancing drug development for schizophrenia and related disorders.
• Further research and validation are necessary to establish reliable neuroimaging biomarkers for clinical use.
• Novel neuroimaging approaches may enable predictive, individualized biomarkers in the future.